New drug combo aims to make bone marrow transplant safer for rare blood cancer patients
NCT ID NCT07104799
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This early-phase study tests whether the drug momelotinib is safe for people with myelofibrosis (a rare bone marrow cancer) who are getting a stem cell transplant. About 28 adults with advanced disease will receive the drug during and after transplant to find the best dose and check for side effects. The goal is to see if adding momelotinib can help control the disease without causing serious harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.